Hosted on MSN

Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern

Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35. The firm said recent stumbles ...
GEN

Schrödinger Halts Cancer Drug Program after Two Patients Die in Phase I Trial

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the cell division cycle 7 (CDC7) inhibitor died in a Phase I trial. The trial (NCT05961839) ...